Clinical outcomes of lutetium-177-vipivotide tetraxetan in men with metastatic castration-resistant prostate cancer at a single academic center.

Authors: Adam Khorasanchi, Jinesh S. Gheeya, Timothy D. Gauntner, Menglin Xu, Elshad Hasanov, Katharine A. Collier, Lingbin Meng, Danielle Elise Zimmerman, Peng Wang, Edmund Folefac, Paul Monk, Amir Mortazavi, Steven K. Clinton, Yuanquan Yang

Published: 2025-02-18

DOI: 10.1200/jco.2025.43.5_suppl.84

Source: Full article

Clinical outcomes of lutetium-177-vipivotide tetraxetan in men with metastatic castration-resistant prostate cancer at a single academic center.

Abstract